Special Issue "Biomarkers for Diagnosis, Complications and Therapy Effects in Civilization Diseases Management"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".

Deadline for manuscript submissions: 21 May 2021.

Special Issue Editors

Prof. Katarzyna Komosinska-Vassev
Website
Guest Editor
Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland
Interests: laboratory medicine; extracellular matrix; civilization diseases; biomarkers
Prof. Pawel Olczyk
Website
Guest Editor
Department of Community Pharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland
Interests: biochemistry and pathobiochemistry of connective tissue

Special Issue Information

Dear Colleagues,

The prevalence of diseases of civilization, i.e., cancer, diabetes, obesity, and autoimmune diseases have shown an exponential worldwide rise in recent years. The development of molecular, biotechnology, and genetic tools has provided to the clinical practice valuable diagnostic tools based on new molecules, proteins, as well as genes, which are not only involved in the pathogenesis of civilization diseases but are also used as markers to assess the effectiveness of therapy or to predict development of complications. Today, a diversity of the available diagnostic tools have helped physicians to change the way of approaching civilization illness toward the concept of personalized medicine. In this Special Issue, we invite investigators to contribute either original research or review articles focusing on the role of new protein, molecular, and genetic markers that can be used for the diagnosis and monitoring of the progression of the several complications linked to civilization diseases as well as biomarkers useful in monitoring the effects of the implemented treatment. At the same time, we invite researchers to submit either original research or review articles having civilization diseases as the main topic focusing on the latest diagnostic tools and possible use of them as biomarkers for health and disease.

Prof. Katarzyna Komosinska-Vassev
Prof. Pawel Olczyk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Civilization diseases
  • Biomarkers
  • Health
  • Disease
  • Molecular pathways
  • Diagnosis
  • Monitoring the effects of treatment
  • Prediction of the development of complications

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

Open AccessReview
Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area
J. Clin. Med. 2021, 10(1), 34; https://doi.org/10.3390/jcm10010034 - 24 Dec 2020
Abstract
Pharmacogenomics (PGx) is the knowledge of diverse drug responses and effects in people, based on their genomic profiles. Such information is considered as one of the main directions to reach personalized medicine in future clinical practices. Since the start of applying next generation [...] Read more.
Pharmacogenomics (PGx) is the knowledge of diverse drug responses and effects in people, based on their genomic profiles. Such information is considered as one of the main directions to reach personalized medicine in future clinical practices. Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body. Yet, the employing of technology is accompanied by big obtained data, which most of them have no clear guidelines for consideration in routine treatment decisions for patients. This review article talks about different types of NGS derived PGx variants in clinical studies and try to display the current and newly developed approaches to deal with pharmacogenetic data with/without clear guidelines for considering in clinical settings. Full article
Show Figures

Graphical abstract

Other

Jump to: Review

Open AccessSystematic Review
Pharmacogenomic Biomarkers of Follicle-Stimulating Hormone Receptor Malfunction in Females with Impaired Ovarian Response—A Genetic Survey
J. Clin. Med. 2021, 10(2), 170; https://doi.org/10.3390/jcm10020170 - 06 Jan 2021
Abstract
Follicle-stimulating hormone receptor (FSHR) plays an essential role as one of the most important molecules in response to some of infertility related medications. Impaired ovarian reserve and poor response to such treatments are partially dependent on the FSHR molecule itself. However, the function [...] Read more.
Follicle-stimulating hormone receptor (FSHR) plays an essential role as one of the most important molecules in response to some of infertility related medications. Impaired ovarian reserve and poor response to such treatments are partially dependent on the FSHR molecule itself. However, the function and drug sensitivity for this receptor may change due to various allele and polymorphisms in the FSHR gene. Studies indicated some of the FSHR-mediated treatments utilized in clinical centers display different outcomes in specific populations, which may arise from FSHR altered genotypes in certain patients. To support the increased demands for reaching the personalized drug and hormone therapy in clinics, focusing on actionable variants through Pharmacogenomic analysis of this receptor may be necessary. The current study tries to display a perspective view on genetic assessments for Pharmacogenomic profiling of the FSHR gene via providing a systematic and critical overview on the genetics of FSHR and its diverse responses to ligands for infertility treatment in females with impaired ovarian responses and show the potential effects of the patient genetic make-up on related binding substances efficacy. All identified functional drug-related alleles were selected through a comprehensive literature search and analyzed. Advanced technologies for the genetic evaluation of them are also discussed properly. Full article
Show Figures

Graphical abstract

Back to TopTop